AVA032 / Avacta - LARVOL DELTA

Avacta to present promising new data from Affimer and pre|CISION platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) - "Avacta Group plc...today announces that it will be presenting two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place on 11-15 October 2023 in Boston Massachusetts....'AVA032, our anti-PD-L1 Affimer® fused to the pro-inflammatory cytokine interleukin 15 (IL-15) displays encouraging efficacy when tested in multiple models of immunomodulation, stimulating a potent immune response and reversing the immunosuppressive tumour microenvironment.'"

Preclinical • Oncology